Literature DB >> 26420996

Radiosynovectomy of Proximal Interphalangeal Joint Synovitis in Rheumatoid Arthritis Treated with Rhenium-188 Labeled Tin-colloid and Imaging with Single-photon Emission Computerized Tomography/Computed Tomography: A First Case Report.

Koramadai Karuppusamy Kamaleshwaran1, Venkataraman Rajamani2, Boopathi Krishnan3, Madhav Mallia4, Radhakrishnan Kalarikal1, Vyshakh Mohanan1, Ajit Sugunan Shinto1.   

Abstract

Rheumatoid arthritis (RA) is a chronic disease that is mainly characterized by the asymmetric erosive synovitis, particularly affecting peripheral joints. Radiation synovectomy or radiosynovectomy (RSV), also known as radiosynoviorthesis was first described in 1950's as an adjuvant treatment for RA. RSV is based on the irradiation of the joint synovium by the intra-articular administration of various β-emitting radiopharmaceuticals. As a generator-produced β-emitting radionuclide, the importance of rhenium-188 (Re-188) for radionuclide therapy is increasing rapidly. There are previous reports which used Re-188 tin colloid in knee joint synovitis, but use of Re-188 tin colloid in small joint is not yet reported. We describe the use of Re-188 tin colloid in a 45-year-old female who presented with right 4(th) proximal interphalangeal joint synovitis due to rheumatoid arthritis.

Entities:  

Keywords:  Radiosynovectomy; rhenium-188 tin colloid; single-photon emission computerized tomography/computed tomography; small joint

Year:  2015        PMID: 26420996      PMCID: PMC4564928          DOI: 10.4103/1450-1147.161730

Source DB:  PubMed          Journal:  World J Nucl Med        ISSN: 1450-1147


Introduction

Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory joint disorder, the primary treatment for which consists of medical regimens aimed at controlling synovial inflammation of the joint.[1] Radiation synovectomy (RSV) involving a radiopharmaceutical injection into the joint. Its intention is to destroy the inflamed synovium, in the expectation that the regenerated synovium will be disease-free, and the symptoms will thereby be alleviated.[2] Rhenium-188 (Re-188) is considered to be a promising radionuclide for use in RSV of joints owing to its favorable decay characteristics. Re-188 is readily available on routine bases from the tungsten-188/Re-188 generator system,[3] which has a useful shelf-life of several months. Re-188 tin colloid RSV is a useful treatment modality in patients with chronic inflammatory knee joint conditions refractory to conventional treatment.[4] We describe the first case of application of Re-188 tin colloid in the treatment of small joint synovitis in RA.

Case Report

A 45-year-old female patient, on treatment for RA, presented with right 4th proximal interphalangeal (PIP) joint pain and swelling [Figure 1] for duration of 6 months. She was treated with antirheumatoid drugs and had no symptom relief. She was referred for three-phase bone scintigraphy and RSV. Blood pool images [Figure 2a] and delayed images [Figure 2b] show increased blood pooling and uptake in the right 4th PIP joint consistent with synovitis. RSV injection was performed according to EANM guidelines.[5] RSV was performed with precise intra-articular injection of a typical dose of 370 MBq Re-188 tin colloid under sterile conditions and fluoroscopic guidance. Before joint puncture, local anesthesia was administered with 2% lidocaine hydrochloride. Prior to the injection of Re-188 tin colloid, Depo Medrol (10 mg in 0.2 mL) was injected into the joint in order to reduce the risk of acute radiation-induced synovitis and to avoid skin radiation necrosis. Subsequently, 370 MBq dispersed in 0.5 mL of sterile, apyrogenic normal saline was administered intra-articularly into ankle, subtalar and calcaneocuboid joint and then the needle was flushed with 0.3 mL of normal saline. Arthrography was performed to check the correct location. An orthopedic bandage was applied as a semi-rigid splint. Images were acquired in a dual head γ camera (Siemens Symbia True point) in the high energy general purpose collimator with 155 ± 20 KeV. Re-188 tin colloid single-photon emission computerized tomography/computed tomography images [Figure 3] showed good distribution of the tracer in the right 4th PIP joint. Her finger was immobilized for 48 h. On the follow-up, after 3 months, pain and swelling of the joint decreased significantly.
Figure 1

Picture showing swelling in the right 4th proximal interphalangeal joint

Figure 2

Anterior and posterior blood pool images (a) and delayed images (b) demonstrates increased blood pool concentration and uptake in right 4th proximal interphalangeal joint consistent with synovitis (arrows)

Figure 3

Coronal computed tomography (a), single-photon emission computerized tomography (b), fused single-photon emission computerized tomography/computed tomography (c) and maximum intensity projection image (d) rhenium-188 tin colloid images of hand showing good tracer distribution in the right 4th proximal interphalangeal joint

Picture showing swelling in the right 4th proximal interphalangeal joint Anterior and posterior blood pool images (a) and delayed images (b) demonstrates increased blood pool concentration and uptake in right 4th proximal interphalangeal joint consistent with synovitis (arrows) Coronal computed tomography (a), single-photon emission computerized tomography (b), fused single-photon emission computerized tomography/computed tomography (c) and maximum intensity projection image (d) rhenium-188 tin colloid images of hand showing good tracer distribution in the right 4th proximal interphalangeal joint

Discussion

Radiation synovectomy is a local intra-articular injection of radionuclides in colloidal form. RSV may relieve synovitis, joint pain, knee flexibility, and joint effusion in about 60–80% of the cases.[6] First used by Fellinger and Schmid[7] in 1952, the technique has been applied for over 50 years in the treatment of resistant synovitis in individual joints after the failure of long-term systemic pharmacotherapy and intra-articular steroid injections. Radioisotopes with emission of β radiation have the capacity to diminish the inflammatory process and ablate the inflamed synovial membrane (pannus) with subsequent fibrosis. Three radionuclides are currently in use: Yttrium-90 (Y-90 silicate/citrate), rhenium-186 (sulfide), and erbium-169 (citrate), which have been indicated for large, medium, and small joints, respectively.[8] Rhenium-188 is an attractive radionuclide for RSV because of its suitable chemistry, t1/2 = 16.9 h and average β energy of 776 keV (Emax = 2.11 MeV, 79%). These properties enable ankle treatment due to its maximal tissue penetration of 11 mm, and its mean range of 3.8 mm.[9] Re-188 decays to the stable Osmium-188, with a γ ray emission of 155 KeV (15%) that is suitable for image acquisition. Leakage has been particularly difficult to quantify where the isotope used was Y-90 or P-32, radioisotopes which are both pure β emitters with no accompanying γ emissions that might be used to quantify biodistribution and dosimetry. This fact allows target uptake evaluation, as well as the estimation of the absorbed radiation dose. Besides this, Re-188 is readily available on routine bases from the tungsten-188/Re-188 generator system which has a useful shelf-life of several months.[39] Rhenium-188 tin colloid can be potentially used as an ideal agent for RSV of the joints. Weigh approximately 30 mg of stannous chloride in a clean vial. Add the required quantity of sterile water for injection such that the final concentration is of stannous solution is 20 mg/mL. Add 0.5 mL of required amount of Re-188 activity into a clean vial containing 0.5 mL of freshly prepared stannous chloride solution. Mix the solution well, cap the vial and then heat it at 100°C for 2 h. After cooling, add the required amount of 0.2 M phosphate buffer to adjust pH of the final preparation to 8. As per the limited number of stability and animal studies performed by the scientists, it has been observed that Re-188 tin colloid is highly stable, and leakage from the synovial site is negligible compared to Re-188 sulfur colloid.[10] Study by Savio et al.[11] and Jeong et al.[12] concluded that Re-188 Sn colloid could be selected as the best formulation for synovectomy therapy taking into account ease of labeling procedure, kit formulation, minimum facilities required, suitable physical and biological characteristics, and the lowest absorbed dose for the patient. Because of this, the highest benefit/risk relation was found for Re-188 Sn in comparison with Re-188 ferric hydroxide macro aggregates coated with tin colloid and Re-188 hydroxyapatite particles. In a study by Shin et al.,[13] Ovalbumin-induced arthritic rabbits, the Re-188 tin colloid improved the macroscopic, the histological score and reduced the knee joint diameter when compared to the arthritic control.

Conclusion

A Re-188 tin colloid is considered as a strong candidate for RSV with a superior efficacy and safety. Lee et al. performed first human study of RSV using Re-188 tin colloid in 22 knees from 21 RA patients refractory to intra-articular corticosteroid injection.[14] No clinical side effects or abnormalities in leukocyte count, platelet count, liver function tests or urine analysis were observed in any patient. In conclusion, in that first study of RSV using Re-188 tin colloid for patients with RA, the treatment resulted in the improvement of arthritis and was well-tolerated. Shin et al. showed RSV using Re-188 tin colloid in refractory RA patients improved magnetic resonance imaging findings as well as clinical parameters.[15] Shamim et al.[4] studied 61 knee joints in 48 patients with chronic synovitis caused by various inflammatory knee joint diseases refractory to conventional therapy. They concluded Re-188 tin colloid RSV is a useful treatment modality in patients with chronic inflammatory knee joint conditions refractory to conventional treatment. Patients with shorter duration of disease, normal or minor X-ray findings, little or no swelling, mild tenderness, and better mobility are better candidates for RSV. Hence, till now, all studies were done on knee synovitis. Our case describes the use of Re-188 tin colloid in small joint synovitis and our patient has good response to therapy.
  14 in total

1.  Long-term results of radiation synovectomy: a clinical follow-up study.

Authors:  W U Kampen; W Brenner; S Kroeger; J A Sawula; K H Bohuslavizki; E Henze
Journal:  Nucl Med Commun       Date:  2001-02       Impact factor: 1.690

2.  EANM procedure guidelines for radiosynovectomy.

Authors:  G Clunie; M Fischer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03       Impact factor: 9.236

3.  [Local therapy of rheumatic diseases].

Authors:  K FELLINGER; J SCHMID
Journal:  Wien Z Inn Med       Date:  1952-09

4.  Preparation of rhenium-188-tin colloid as a radiation synovectomy agent and comparison with rhenium-188-sulfur colloid.

Authors:  J M Jeong; Y J Lee; Y J Kim; Y S Chang; D S Lee; J K Chung; Y W Song; M C Lee
Journal:  Appl Radiat Isot       Date:  2000-04       Impact factor: 1.513

Review 5.  Radiation synovectomy revisited.

Authors:  E Deutsch; J W Brodack; K F Deutsch
Journal:  Eur J Nucl Med       Date:  1993-11

6.  Radiation synovectomy using 188Re-tin colloid improves knee synovitis as shown by MRI in refractory rheumatoid arthritis.

Authors:  Kichul Shin; Jung Chan Lee; Hyo Jin Choi; Jae Min Jeong; Miwon Son; Yun Jong Lee; Eun Bong Lee; Sung Hwan Hong; Yeong Wook Song
Journal:  Nucl Med Commun       Date:  2007-04       Impact factor: 1.690

7.  DA-7911, 188Rhenium-tin colloid, as a new therapeutic agent of rheumatoid arthritis.

Authors:  Chang Yell Shin; Miwon Son; Jun Il Ko; Mi Young Jung; In Ki Lee; Soon Hoe Kim; Won Bae Kim; Jae Min Jeong; Yeong Wook Song
Journal:  Arch Pharm Res       Date:  2003-02       Impact factor: 4.946

8.  Treatment of rheumatoid arthritis using radiopharmaceuticals.

Authors:  J D Zuckerman; C B Sledge; S Shortkroff; P Venkatesan
Journal:  Int J Rad Appl Instrum B       Date:  1987

9.  Physico-chemical characterisation and biological evaluation of 188-Rhenium colloids for radiosynovectomy.

Authors:  Ma Ures; Eduardo Savio; Antonio Malanga; Marcelo Fernández; Andrea Paolino; Javier Gaudiano
Journal:  BMC Nucl Med       Date:  2002-10-14

10.  188Re radiopharmaceuticals for radiosynovectomy: evaluation and comparison of tin colloid, hydroxyapatite and tin-ferric hydroxide macroaggregates.

Authors:  Eduardo Savio; María Cristina Ures; Patricia Zeledón; Victoria Trindade; Andrea Paolino; Virginia Mockford; Antonio Malanga; Marcelo Fernández; Javier Gaudiano
Journal:  BMC Nucl Med       Date:  2004-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.